Prime Medicine reports new preclinical data demonstrating the ability of prime editors to efficiently and precisely correct the predominant mutations that cause rhodopsin-associated autosomal dominant ...
Editas Medicine presents preclinical data on gene editing at ASGCT, aiming to develop candidates for hematopoietic and liver therapies by 2025. Editas Medicine, Inc. announced its progress in the ...
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing Phase 2 trial for NTLA-2002, a CRISPR-based gene editing therapy for an ...
Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant advancements ...
CRISPR-based genome engineering revolutionized the gene-editing field by making experimental workflows considerably easier, faster, and more efficient than previous methods. Still, generating reliable ...
Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results